Lumida
/KALV
⌘K
Kalvista Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

KALV
$27.00USD↑+0.00%+0.00 today

MARKET CAP

1.4B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$27 – $27

52W RANGE

$27$27

AI Summary

Stalk
StalkMedium

KALV remains in a Stage 2 advancing regime underpinned by a strong parabolic acceleration, reinforcing a bullish medium-term bias. However, price is severely extended above rising short-term EMAs with RSI and Options Score in extreme overbought territory, signaling near-term exhaustion risk. Execution should be deferred and staged on meaningful pullbacks into the rising EMA zone or the recent breakout support area.

  • ↑Q1 Ectorly sales of $1.4M show strong launch demand
  • ↑5% of US HAE patients submitted prescriptions within weeks
  • ↓Operating expenses at $60.4M weigh on margins and cash burn
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

KalVista Pharmaceuticals (NASDAQ: KALV), a prominent player in the biopharmaceutical industry, is focused on providing innovative therapies for hereditary angioedema (HAE). The company is currently transforming the HAE treatment landscape with its first oral on-demand medication, Ectorly, which received FDA approval last year. Recently, KalVista has been acquired by Chiesi Group, further bolstering its market position and expanding its capabilities to address unmet medical needs in HAE treatment.

Bull says

  • ↑Q1 Ectorly sales of $1.4M show strong launch demand
  • ↑5% of US HAE patients submitted prescriptions within weeks
  • ↑International rollouts in Germany and UK underway to drive growth
  • ↑Cash balance of $191M supports operations and expansion plans
  • ↑50% of switchers have high-burden HAE, driving higher refill rates
  • ↑Clean factor profile offers upside without legacy performance drag

Bear says

  • ↓Operating expenses at $60.4M weigh on margins and cash burn
  • ↓Payer coverage policies can take six months, delaying revenue
  • ↓Seasonal demand swings risk uneven adoption rates
  • ↓Established injectable therapies may retain patient loyalty
  • ↓Opacity in performance metrics raises uncertainty on execution
  • ↓Competitive pressure looms from established HAE treatment providers

Investment themes with KALV

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q3 2025 · Mgmt. Guidance

Updated 04-29-2026neutral

Transcript signals

Bull points

  • We are highly encouraged by Ectoly's first three months on the U.S. market. Adoption has been steady and linear with real world utilization tracking as we expected. The takeaways are clear. Demand for Ecterly is strong. It is being used to treat a significant number of HAE attacks, and it is meeting the expectations of people living with HAE for a highly efficacious and safe therapeutic alternative.
  • We continue to believe that Ecterly will evolve to become the foundational treatment for HAE.
  • In addition, We are executing on our mission to bring Ectoly to people living with HAE globally.

Bear points

  • When looking at gross to net, I'd note it came in towards the low end of our expected range this quarter, driven largely by lower copay utilization typical for this time of year.
  • total operating expenses for the period were $59.7 million, consisting of approximately $12 million in RDA expenses and approximately $46.5 million in SG&A expenses.
  • we are planning to, I would say, wrap up discussions with some of the larger payers in PBMs. with an aim to have policies in place, again, early in 2026.
Read full transcript analysis ›